Taysha Gene Therapies to Participate in Upcoming May Investor Healthcare Conferences
Txylo.com/10130843

Trending...
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference and a virtual presentation at the Oppenheimer Rare & Orphan Disease Summit.



Conference Details:



Event:



2021 RBC Capital Markets Global Healthcare Conference



Date:



Wednesday, May 19, 2021



Time:



3:05 pm ET



Format:



Fireside chat



Participants:



More on Txylo.com
RA Session II, President, Founder and CEO





Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development





Kamran Alam, Chief Financial Officer







Event:



Oppenheimer Rare & Orphan Disease Summit



Date:



Friday, May 21, 2021



Time:



4:35 pm ET



Format:



Presentation



Participants:



RA Session II, President, Founder and CEO





Dr. Suyash Prasad, Chief Medical Officer and Head of Research and Development

More on Txylo.com




Kamran Alam, Chief Financial Officer


Webcasts for these conferences will be available in the "Events & Media" section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients' lives. More information is available at www.tayshagtx.com.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on Txylo.com